{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013932","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.083215+00:00","generated_at":"2026-06-12T03:32:35.578103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Azenta Q3 revenue up 25% YoY to $166M; guides Q4 $155-173M","bullets":["Revenue $166M, up 25% YoY; organic growth 2%; Life Sciences Products +57%, Services +7%.","GAAP diluted EPS from cont ops ($0.04); non-GAAP diluted EPS $0.13, up from $0.12 YoY.","Adjusted EBITDA $13M (7.8% margin); free cash flow $9M in quarter.","Q4 FY2023 guidance: total revenue $155-173M, non-GAAP EPS ($0.02)-$0.06.","FYTD repurchased 16M shares for $764M; on track for $1B buyback by end of CY2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013932","json":"https://secwatch.observer/filing/0001558370-23-013932.json","markdown":"https://secwatch.observer/filing/0001558370-23-013932.md","text":"https://secwatch.observer/filing/0001558370-23-013932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000155837023013932/0001558370-23-013932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000155837023013932/azta-20230808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:32:35.578103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ec35ea54e7fdf6f1c79ca16aaa947c21c6b75ec","claim":"Azenta, Inc. reported fourth quarter of fiscal 2023 results: revenue $155 to $173 million, EPS ($0.02) to $0.06. Guidance initiated.","evidence_excerpt":"Total revenue is expected to be in the range of $155 to $173 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/933974/000155837023013932/0001558370-23-013932-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of fiscal 2023"},{"label":"Revenue","value":"$155 to $173 million"},{"label":"EPS","value":"($0.02) to $0.06"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"fdc9f4fb2db389da63dd648f073aa1f7c01f9c2c","claim":"Azenta, Inc. reported third quarter ended June 30, 2023 results: revenue $166 million, EPS ($0.04).","evidence_excerpt":"confident in the unique value we bring to our customer partnerships across pharmaceutical, biotech, and academic institutions.” ​ Third Quarter Fiscal 2023 Results ● Revenue was $166 million, up 25% year over year and 12% sequentially. Organic revenue increased 2% year over year, which excludes the impacts from foreign exchange headwinds of less than 1 percent and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/933974/000155837023013932/0001558370-23-013932-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended June 30, 2023"},{"label":"Revenue","value":"$166 million"},{"label":"EPS","value":"($0.04)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}